IRTC vs. TNDM, PRCT, AXNX, NARI, ICUI, NVCR, IART, LMAT, ATEC, and INSP
Should you be buying iRhythm Technologies stock or one of its competitors? The main competitors of iRhythm Technologies include Tandem Diabetes Care (TNDM), PROCEPT BioRobotics (PRCT), Axonics (AXNX), Inari Medical (NARI), ICU Medical (ICUI), NovoCure (NVCR), Integra LifeSciences (IART), LeMaitre Vascular (LMAT), Alphatec (ATEC), and Inspire Medical Systems (INSP). These companies are all part of the "surgical & medical instruments" industry.
Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Tandem Diabetes Care presently has a consensus price target of $43.80, indicating a potential downside of 7.40%. iRhythm Technologies has a consensus price target of $134.00, indicating a potential upside of 41.31%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.
In the previous week, Tandem Diabetes Care had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 4 mentions for Tandem Diabetes Care and 2 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.13 beat Tandem Diabetes Care's score of 0.53 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
Tandem Diabetes Care has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Tandem Diabetes Care received 179 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.04% of users gave iRhythm Technologies an outperform vote while only 61.01% of users gave Tandem Diabetes Care an outperform vote.
Tandem Diabetes Care has a net margin of -18.37% compared to Tandem Diabetes Care's net margin of -25.33%. iRhythm Technologies' return on equity of -34.38% beat Tandem Diabetes Care's return on equity.
Summary
Tandem Diabetes Care beats iRhythm Technologies on 10 of the 16 factors compared between the two stocks.
Get iRhythm Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iRhythm Technologies Competitors List
Related Companies and Tools
